Research ExplorerPublicationsValve-in-valve procedures for degenerated surgical and trans...

Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve

Standard

Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve. / Schaefer, Andreas; Demal, Till Joscha; Bhadra, Oliver D; Grundmann, David; Voigtländer, Lisa; Waldschmidt, Lara; Schirmer, Johannes; Pecha, Simon; Schneeberger, Yvonne; Schofer, Niklas; Sörensen, Nils; Blankenberg, Stefan; Reichenspurner, Hermann; Seiffert, Moritz; Conradi, Lenard.

In: FRONT CARDIOVASC MED, Vol. 10, 2023, p. 1209184.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schaefer, A, Demal, TJ, Bhadra, OD, Grundmann, D, Voigtländer, L, Waldschmidt, L, Schirmer, J, Pecha, S, Schneeberger, Y, Schofer, N, Sörensen, N, Blankenberg, S, Reichenspurner, H, Seiffert, M & Conradi, L 2023, 'Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve', FRONT CARDIOVASC MED, vol. 10, pp. 1209184. https://doi.org/10.3389/fcvm.2023.1209184

APA

Schaefer, A., Demal, T. J., Bhadra, O. D., Grundmann, D., Voigtländer, L., Waldschmidt, L., Schirmer, J., Pecha, S., Schneeberger, Y., Schofer, N., Sörensen, N., Blankenberg, S., Reichenspurner, H., Seiffert, M., & Conradi, L. (2023). Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve. FRONT CARDIOVASC MED, 10, 1209184. https://doi.org/10.3389/fcvm.2023.1209184

Vancouver

Schaefer A, Demal TJ, Bhadra OD, Grundmann D, Voigtländer L, Waldschmidt L et al. Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve. FRONT CARDIOVASC MED. 2023;10:1209184. https://doi.org/10.3389/fcvm.2023.1209184

Bibtex

@article{83c2bf78fa604a5fb7391db918336229,
title = "Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve",
abstract = "BACKGROUND: Valve-in-valve (ViV) transfemoral transcatheter aortic valve implantation (TAVI) for failing aortic surgical bioprostheses or transcatheter heart valves (THV) has demonstrated a reasonable clinical and hemodynamic efficacy. Traditionally, self-expanding (SE) supra-annular THV are considered to result in superior hemodynamics compared with balloon-expandable intra-annular THV after ViV. However, so far no data are found on latest-generation intra-annular SE THV for aortic ViV procedures which might be superior with regard to coronary access or subsequent valve reintervention.AIM: We herein aim to evaluate a latest-generation SE intra-annular THV for aortic ViV procedures.MATERIALS AND METHODS: Between May 2022 and November 2022, five consecutive patients (4/5 female with mean age of 76.2 years and mean Society of Thoracic Surgeons predicted risk of mortality score of 2.9%) received ViV TAVI using the Navitor system (Abbott, Chicago, IL, USA) for treatment of failing surgical bioprostheses or THV. Data were retrospectively analyzed according to updated Valve Academic Research Consortium 3 (VARC-3) definitions.RESULTS: At 30 days, absence of mortality and VARC-3 adjudicated clinical endpoints were documented. Echocardiography at 30 days revealed complete absence of paravalvular leakage and single-digit mean transvalvular gradients (mean of 6.0 mmHg) in all patients.CONCLUSION: The investigated intra-annular SE THV results in excellent 30-day outcomes for aortic ViV procedures for failing surgical bioprostheses or THV. Despite the intra-annular design, hemodynamic results were excellent, even in small bioprostheses. Ease of use of this valve platform is reflected by only two cycles of resheathing in five ViV procedures with hemodynamic stability during all steps of valve deployment.",
author = "Andreas Schaefer and Demal, {Till Joscha} and Bhadra, {Oliver D} and David Grundmann and Lisa Voigtl{\"a}nder and Lara Waldschmidt and Johannes Schirmer and Simon Pecha and Yvonne Schneeberger and Niklas Schofer and Nils S{\"o}rensen and Stefan Blankenberg and Hermann Reichenspurner and Moritz Seiffert and Lenard Conradi",
note = "{\textcopyright} 2023 Schaefer, Demal, Bhadra, Grundmann, Voigtl{\"a}ender, Waldschmidt, Schirmer, Pecha, Schneeberger, Schofer, S{\"o}rensen, Blankenberg, Reichenspurner, Seiffert and Conradi.",
year = "2023",
doi = "10.3389/fcvm.2023.1209184",
language = "English",
volume = "10",
pages = "1209184",
journal = "FRONT CARDIOVASC MED",
issn = "2297-055X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Valve-in-valve procedures for degenerated surgical and transcatheter aortic valve bioprostheses using a latest-generation self-expanding intra-annular transcatheter heart valve

AU - Schaefer, Andreas

AU - Demal, Till Joscha

AU - Bhadra, Oliver D

AU - Grundmann, David

AU - Voigtländer, Lisa

AU - Waldschmidt, Lara

AU - Schirmer, Johannes

AU - Pecha, Simon

AU - Schneeberger, Yvonne

AU - Schofer, Niklas

AU - Sörensen, Nils

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Seiffert, Moritz

AU - Conradi, Lenard

N1 - © 2023 Schaefer, Demal, Bhadra, Grundmann, Voigtläender, Waldschmidt, Schirmer, Pecha, Schneeberger, Schofer, Sörensen, Blankenberg, Reichenspurner, Seiffert and Conradi.

PY - 2023

Y1 - 2023

N2 - BACKGROUND: Valve-in-valve (ViV) transfemoral transcatheter aortic valve implantation (TAVI) for failing aortic surgical bioprostheses or transcatheter heart valves (THV) has demonstrated a reasonable clinical and hemodynamic efficacy. Traditionally, self-expanding (SE) supra-annular THV are considered to result in superior hemodynamics compared with balloon-expandable intra-annular THV after ViV. However, so far no data are found on latest-generation intra-annular SE THV for aortic ViV procedures which might be superior with regard to coronary access or subsequent valve reintervention.AIM: We herein aim to evaluate a latest-generation SE intra-annular THV for aortic ViV procedures.MATERIALS AND METHODS: Between May 2022 and November 2022, five consecutive patients (4/5 female with mean age of 76.2 years and mean Society of Thoracic Surgeons predicted risk of mortality score of 2.9%) received ViV TAVI using the Navitor system (Abbott, Chicago, IL, USA) for treatment of failing surgical bioprostheses or THV. Data were retrospectively analyzed according to updated Valve Academic Research Consortium 3 (VARC-3) definitions.RESULTS: At 30 days, absence of mortality and VARC-3 adjudicated clinical endpoints were documented. Echocardiography at 30 days revealed complete absence of paravalvular leakage and single-digit mean transvalvular gradients (mean of 6.0 mmHg) in all patients.CONCLUSION: The investigated intra-annular SE THV results in excellent 30-day outcomes for aortic ViV procedures for failing surgical bioprostheses or THV. Despite the intra-annular design, hemodynamic results were excellent, even in small bioprostheses. Ease of use of this valve platform is reflected by only two cycles of resheathing in five ViV procedures with hemodynamic stability during all steps of valve deployment.

AB - BACKGROUND: Valve-in-valve (ViV) transfemoral transcatheter aortic valve implantation (TAVI) for failing aortic surgical bioprostheses or transcatheter heart valves (THV) has demonstrated a reasonable clinical and hemodynamic efficacy. Traditionally, self-expanding (SE) supra-annular THV are considered to result in superior hemodynamics compared with balloon-expandable intra-annular THV after ViV. However, so far no data are found on latest-generation intra-annular SE THV for aortic ViV procedures which might be superior with regard to coronary access or subsequent valve reintervention.AIM: We herein aim to evaluate a latest-generation SE intra-annular THV for aortic ViV procedures.MATERIALS AND METHODS: Between May 2022 and November 2022, five consecutive patients (4/5 female with mean age of 76.2 years and mean Society of Thoracic Surgeons predicted risk of mortality score of 2.9%) received ViV TAVI using the Navitor system (Abbott, Chicago, IL, USA) for treatment of failing surgical bioprostheses or THV. Data were retrospectively analyzed according to updated Valve Academic Research Consortium 3 (VARC-3) definitions.RESULTS: At 30 days, absence of mortality and VARC-3 adjudicated clinical endpoints were documented. Echocardiography at 30 days revealed complete absence of paravalvular leakage and single-digit mean transvalvular gradients (mean of 6.0 mmHg) in all patients.CONCLUSION: The investigated intra-annular SE THV results in excellent 30-day outcomes for aortic ViV procedures for failing surgical bioprostheses or THV. Despite the intra-annular design, hemodynamic results were excellent, even in small bioprostheses. Ease of use of this valve platform is reflected by only two cycles of resheathing in five ViV procedures with hemodynamic stability during all steps of valve deployment.

U2 - 10.3389/fcvm.2023.1209184

DO - 10.3389/fcvm.2023.1209184

M3 - SCORING: Journal article

C2 - 37727306

VL - 10

SP - 1209184

JO - FRONT CARDIOVASC MED

JF - FRONT CARDIOVASC MED

SN - 2297-055X

ER -